Canada markets closed

Kindred Biosciences, Inc. (KIN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0500-0.1400 (-3.34%)
At close: 4:00PM EDT

3.9900 -0.06 (-1.48%)
After hours: 6:59PM EDT

Kindred Biosciences, Inc.

1555 Bayshore Highway
Suite 200
Burlingame, CA 94010
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees156

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard ChinCo-Founder, CEO & Director899kN/A1967
Ms. Denise M. BeversCo-Founder, Sec. & Director633.13kN/A1967
Ms. Wendy K. WeeChief Financial Officer438.15kN/A1953
Dr. Hangjun ZhanChief Scientific Officer432.98kN/A1960
Ms. Katja BuhrerChief of Staff, VP of Corp. Devel. & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

Corporate Governance

Kindred Biosciences, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.